- In surprise decision, US approves muscular dystrophy drug CNBC
- Stocks To Watch With Stock Market At Record Highs Include Paycom Software Investor's Business Daily
- Sarepta’s surprise FDA approval for rare disease drug excites investors MarketWatch
- FDA OKs Golodirsen (Vyondys 53) for Duchenne Muscular Dystrophy Medscape
- Sarepta Therapeutics Stock Eyes Best Day in 3 Years on FDA Reversal Schaeffers Research
- View full coverage on Google News
by via Top stories - Google News
No comments:
Post a Comment